HIV vaccine - Chiron/Mitsubishi Pharma

Drug Profile

HIV vaccine - Chiron/Mitsubishi Pharma

Alternative Names: HIV-IT (V)

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator Chiron Technologies
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Oct 2001 Welfide Corporation has merged with Mitsubishi-Tokyo Pharmaceuticals to form Mitsubishi Pharma Corporation
  • 06 Apr 2000 Yoshitomi is now called Welfide Corporation
  • 26 Mar 1998 Discontinued-I for HIV infections treatment in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top